Teva’s New Biosimilar Approvals in Europe
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is thrilled to share that the European Commission has approved its biosimilars PONLIMSI and DEGEVMA, marking a significant development for bone health treatments in the region. This decision builds on the earlier positive opinions from the Committee for Medicinal Products for Human Use (CHMP), setting the stage for a broader availability of these essential medications in Europe.
Expanding Access to Vital Treatments
The approvals of PONLIMSI and DEGEVMA signal a pivotal moment in Teva's ongoing commitment to enhancing patient care through its strong biosimilars portfolio. These medicines significantly contribute to Teva's Pivot to Growth Strategy, demonstrating the company's dedication to meeting the healthcare needs of patients.
Overview of PONLIMSI and DEGEVMA
PONLIMSI is a biosimilar of Prolia® (denosumab), specifically designed for treating osteoporosis in postmenopausal women and men at increased fracture risk. It is also indicated for men experiencing bone loss due to hormone ablation in prostate cancer and for those on long-term systemic glucocorticoids. This medication will be available as a 60mg/1mL solution for injection.
Mechanism of Action
Denosumab, the active component in PONLIMSI, works by targeting RANKL, a protein crucial for the health and function of osteoclasts, the cells that break down bone. By inhibiting RANKL, PONLIMSI effectively reduces bone resorption, allowing for improved bone health in patients.
Launch Plans for the New Products
Teva plans to introduce both PONLIMSI and DEGEVMA to key European markets soon, aiming to provide more treatment options for those managing serious bone conditions. DEGEVMA, a biosimilar to Xgeva® (denosumab), aims to prevent bone complications in advanced cancer patients and is suitable for treating skeletal issues in adolescents and adults with giant cell tumors.
Quality and Efficacy
Both PONLIMSI and DEGEVMA have undergone extensive studies demonstrating their quality, safety, and effectiveness compared to their reference products, ensuring that patients receive top-tier care.
Teva's Commitment to Healthcare
As a premier biopharmaceutical entity, Teva has been at the forefront of innovative healthcare solutions for over 120 years. Their robust generics division enables the company to provide affordable medications while focusing on groundbreaking treatments in various fields including neuroscience and immunology. Teva is committed to addressing patients' needs today and into the future, exemplifying a dedication to improving health outcomes worldwide.
Steffen Nock, SVP Head of Biosimilars, expressed that this approval is a vital step in enhancing patient access to critical therapies, which aligns with Teva’s strategic vision for better care solutions. Michal Nitka, SVP Head Generics Europe, highlighted the company's ongoing commitment to creating additional treatment avenues in markets where accessibility to biosimilars remains a challenge.
Frequently Asked Questions
What are PONLIMSI and DEGEVMA?
PONLIMSI and DEGEVMA are biosimilars developed by Teva aimed at improving treatment options for osteoporosis and preventing bone complications in cancer patients.
How do PONLIMSI and DEGEVMA work?
They work by targeting RANKL, inhibiting bone resorption, thereby promoting better bone health and reducing the risk of fractures.
When will these products be available?
Teva plans to launch PONLIMSI and DEGEVMA across key European markets shortly, expanding patient access to vital therapies.
What is Teva’s commitment to biosimilars?
Teva aims to improve patient care by broadening access to biosimilars, as part of its larger Pivot to Growth Strategy.
How does Teva ensure the safety and efficacy of its biosimilars?
Through comprehensive analytical, preclinical, and clinical trials, Teva demonstrates that its biosimilars have comparable quality, safety, and effectiveness to their reference products.
